Cargando…
Profile of coronavirus disease enlightened asthma as a protective factor against death: An epidemiology study from Brazil during the pandemic
INTRODUCTION: The possibility that asthma is not a risk factor for the worst outcomes due to coronavirus disease (COVID-19) is encouraged. The increase in Th2 response dominance can downregulate the late phase of hyperinflammation, which is typically the hallmark of more severe respiratory viral inf...
Autores principales: | Sansone, Nathalia Mariana Santos, Valencise, Felipe Eduardo, Bredariol, Rafael Fumachi, Peixoto, Andressa Oliveira, Marson, Fernando Augusto Lima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745079/ https://www.ncbi.nlm.nih.gov/pubmed/36523782 http://dx.doi.org/10.3389/fmed.2022.953084 |
Ejemplares similares
-
Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil
por: Sansone, Nathália Mariana Santos, et al.
Publicado: (2022) -
Epidemiologic Profile of Severe Acute Respiratory Infection in Brazil During the COVID-19 Pandemic: An Epidemiological Study
por: Sansone, Nathália Mariana Santos, et al.
Publicado: (2022) -
Characterization of demographic data, clinical signs, comorbidities, and outcomes according to the race in hospitalized individuals with COVID-19 in Brazil: An observational study
por: Sansone, Nathália MS, et al.
Publicado: (2022) -
Retraction of Clinical Trials about the SARS-CoV-2 Infection: An Unaddressed Problem and Its Possible Impact on Coronavirus Disease (COVID)-19 Treatment
por: Valencise, Felipe Eduardo, et al.
Publicado: (2023) -
Hospitalized patients with X-linked disease and infected with SARS-CoV-2 in Brazil: A serial case report from the first two years of the pandemic
por: Boschiero, Matheus Negri, et al.
Publicado: (2023)